Guerrero J M, Goberna R, Molinero P, Jimenez J, Calvo J R
Biosci Rep. 1986 Jun;6(6):579-84. doi: 10.1007/BF01114955.
Bovine thymic peptide extract (1-100 micrograms/ml) is shown to completely inhibit the binding of [125I]VIP to rat blood mononuclear cells, lymphoid cells of spleen, and liver plasma membranes. In the three models, the bovine thymic peptide extract inhibits [125I]VIP binding with a potency that is 4000-7000 times lower than that of the native VIP, on a weight basis. In rat liver plasma membranes, the bovine thymic peptide extract stimulates adenylate cyclase with a maximal efficiency that is similar to that of VIP. At maximal doses, VIP and thymic peptide extract do not exert an additive effect on adenylate cyclase, suggesting that the activation of the enzyme by the bovine thymic peptide extract occurs through VIP receptors. Finally, no VIP-like immunoreactivity was detected in the thymic peptide extract using an antiserum raised against mammalian VIP. All these data suggest the presence in the bovine thymic peptide extract of a new substance which behaves as a VIP agonist in rat.
牛胸腺肽提取物（1 - 100微克/毫升）可完全抑制[125I]血管活性肠肽（VIP）与大鼠血液单核细胞、脾脏淋巴细胞及肝细胞膜的结合。在这三种模型中，按重量计算，牛胸腺肽提取物抑制[125I]VIP结合的效力比天然VIP低4000 - 7000倍。在大鼠肝细胞膜中，牛胸腺肽提取物刺激腺苷酸环化酶的最大效率与VIP相似。在最大剂量时，VIP和胸腺肽提取物对腺苷酸环化酶无相加作用，这表明牛胸腺肽提取物对该酶的激活是通过VIP受体发生的。最后，使用针对哺乳动物VIP产生的抗血清，在胸腺肽提取物中未检测到VIP样免疫反应性。所有这些数据表明，牛胸腺肽提取物中存在一种新物质，该物质在大鼠中表现为VIP激动剂。
